Key result
Micro-dystrophin gene therapy improves survival and cardiac function in DMD mice but triggers cardiac inflammation.
Why the study?
Does micro-dystrophin replacement gene therapy affect cardiac function and inflammation in a severe model of Duchenne muscular dystrophy?
Does micro-dystrophin replacement gene therapy affect cardiac function and inflammation in a severe model of Duchenne muscular dystrophy?
Answers are grounded in this paper and cite their sources.
While micro-dystrophin replacement therapy improves survival and cardiac function in a severe DMD mouse model, it is associated with long-term cardiac inflammation and increased septum thickness.
Micro-dystrophin replacement gene therapy is currently under clinical trials in Duchenne muscular dystrophy (DMD) patients. However, recent adverse cardiac events has led to serious concerns about this therapeutic intervention. We studied the long-term effect of dystrophin replacement strategies in a severe model of DMD (mdx; utrophin-/-mice). Although micro-dystrophin remarkably improved survival and cardiac function after 1 year of treatment, we were able to reveal an increased septum thickness, which is the result of cardiac inflammation. Our data warrant consideration that micro-dystrophin replacement therapy may be associated with cardiac inflammation and opens up perspectives for understanding the consequences of using this approach in DMD patients.
No takes yet. Share an insight, caveat, or question.
Forand et al. (2025) studied Duchenne muscular dystrophy (DMD). Micro-dystrophin replacement gene therapy was evaluated on Survival, cardiac function, and cardiac inflammation (septum thickness). Micro-dystrophin replacement therapy in a severe DMD mouse model improved survival and cardiac function after 1 year but caused increased septum thickness due to cardiac inflammation.
Synapse has enriched 10 related papers. Consider them for comparative context: